Integral Health Asset Management LLC Has $23.99 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Integral Health Asset Management LLC lowered its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 275,000 shares of the biotechnology company's stock after selling 15,000 shares during the quarter. Blueprint Medicines accounts for about 2.0% of Integral Health Asset Management LLC's investment portfolio, making the stock its 11th largest position. Integral Health Asset Management LLC owned about 0.43% of Blueprint Medicines worth $23,986,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Blueprint Medicines by 30.8% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 648,660 shares of the biotechnology company's stock worth $56,576,000 after buying an additional 152,573 shares during the last quarter. Gotham Asset Management LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter worth approximately $309,000. Graham Capital Management L.P. lifted its holdings in shares of Blueprint Medicines by 48.8% during the fourth quarter. Graham Capital Management L.P. now owns 25,260 shares of the biotechnology company's stock worth $2,203,000 after buying an additional 8,283 shares during the last quarter. Granahan Investment Management LLC lifted its holdings in shares of Blueprint Medicines by 8.2% during the fourth quarter. Granahan Investment Management LLC now owns 141,890 shares of the biotechnology company's stock worth $12,376,000 after buying an additional 10,744 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its holdings in shares of Blueprint Medicines by 401.6% during the fourth quarter. Frontier Capital Management Co. LLC now owns 105,130 shares of the biotechnology company's stock worth $9,169,000 after buying an additional 84,171 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BPMC shares. Morgan Stanley started coverage on Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target for the company. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an "outperform" rating for the company. JPMorgan Chase & Co. upped their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Finally, JMP Securities restated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $126.56.

Insiders Place Their Bets

In other news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This represents a 3.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,503 shares of company stock worth $1,027,931 over the last three months. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded up $2.20 during mid-day trading on Friday, hitting $101.69. 581,639 shares of the company were exchanged, compared to its average volume of 781,598. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The business has a fifty day moving average of $89.65 and a 200 day moving average of $94.35. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90. The company has a market capitalization of $6.57 billion, a PE ratio of -94.16 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the prior year, the company earned $1.40 earnings per share. The business's revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.